BioCentury
ARTICLE | Company News

Universite Laval, AmorChem deal

September 1, 2014 7:00 AM UTC

The university granted VC fund AmorChem an exclusive, worldwide license to a gene therapy program to treat Friedreich’s Ataxia. The university plans to optimize the gene therapy and test it in a mouse...